Xeris Biopharma Holdings, Inc. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים XERS

Xeris Biopharma (XERS) momentum is driven by the commercial success of Gvoke and Recorlev, as clearly demonstrated by the annual EPS TTM percentage growth on the GURU.Markets base chart. The current 63.80 metric confirms the efficiency level of XeriSol anhydrous solutions, which simplify injections. Stable management has solidified this trend, confidently steering the business toward a trajectory of operational profitability.
Xeris Biopharma - פילוחים אנליטיים ומדדי מפתח (XERS)

This metric measures the rolling year net income per share dynamics, allowing investors to assess business scaling rates and actual capitalization efficiency. For Xeris Biopharma (XERS), the EPS YoY TTM growth efficiency indicator verifies the financial return on production outsourcing, confirming that the reliability of CMO partner chains is transforming into sustainable growth in shareholder value.